PRIMA-1met (APR-246) inhibits growth of colorectal cancer cells with different p53 status through distinct mechanisms
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
// Xiao-Lan Li 1, 2, * , Jianbiao Zhou 1, * , Zit-Liang Chan 1 , Jing-Yuan Chooi 1 , Zhi-Rong Chen 2 , Wee-Joo Chng 1, 3, 4 1 Cancer Science Institute of Singapore, National University of Singapore, Centre for Translational Medicine, Singapore 117599, Republic of Singapore 2 Department of Gastroenterology, Suzhou Municipal Hospital (Eastern), Suzhou City, Jiangsu Province, 215001, P.R. China 3 Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 119074, Republic of Singapore 4 Department of Hematology-Oncology, National University Hospital, Singapore 119228, Republic of Singapore * These authors have contributed equally to this work Correspondence to: Wee-Joo Chng, e-mail: mdccwj@nus.edu.sg Zhi-Rong Chen, e-mail: czr88188@163.com Keywords: colorectal cancer (CRC), p53, tumor suppressor gene (TSG), PRIMA-1 met , targeted therapy Received: July 14, 2015 Accepted: September 17, 2015 Published: October 01, 2015 ABSTRACT PRIMA-1 met (APR-246) is a methylated derivative and structural analog of PRIMA-1 (p53 re-activation and induction of massive apoptosis). PRIMA-1 met has been reported to restore both the wild type (wt) structure and function of mutant p53. Here, we show that PRIMA-1 met is highly effective at limiting the growth of CRC cells regardless of p53 status. However, PRIMA-1 met induces robust apoptosis only in CRC cells with mutant p53. Upregulation of Noxa, a proapoptotic molecule, is crucial for PRIMA-1 met mediated activity. In human xenograft model of disease, PRIMA-1 met effectively suppresses CRC tumor growth. Our results uncover distinct mechanisms of PRIMA-1 met in CRC with different p53 status, thus providing a mechanistic rationale to evaluate the clinical efficacy of PRIMA-1 met in CRC patients with different p53 status.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound
Bykov, V. J. N., Issaeva, N., Shilov, A., Hultcrantz, M., Pugacheva, E., Chumakov, P., Bergman, J., Wiman, K. G., & Selivanova, G. (2002) · Nature Medicine · doi:10.1038/nm0302-282 · Cited by 1,067 · cited 4×
“These results were consistent with previous studies that demonstrated the ability of PRIMA-1met to restore the mutant p53 to wild-type p53 properties in other cancers [15, 17, 20, 21, 25].”
BackgroundResultInfluentialPRIMA-1 reactivates mutant p53 by covalent binding to the core domain
Lambert, J. M. R., Gorzov, P., Veprintsev, D. B., Söderqvist, M., Segerbäck, D., Bergman, J., Fersht, A. R., Hainaut, P., Wiman, K. G., & Bykov, V. J. N. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.03.003 · Cited by 592
Lehmann, S., Bykov, V. J. N., Ali, D., Andrén, O., Cherif, H., Tidefelt, U., Uggla, B., Yachnin, J., Juliusson, G., Moshfegh, A., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.7783 · Cited by 406 · cited 1×
“PRIMA-1met (APR-246), a methylated and more potent analog of PRIMA-1, has already advanced to a phase I/II clinic trial in hematologic malignancies and prostate cancer [18, 19].”
BackgroundTranslating p53 into the clinic
Cheok, C. F., Verma, C. S., Baselga, J., & Lane, D. P. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.174 · Cited by 381 · cited 1×
“PRIMA-1met (APR-246), a methylated and more potent analog of PRIMA-1, has already advanced to a phase I/II clinic trial in hematologic malignancies and prostate cancer [18, 19].”
Background
Cited by
Targeting p53 pathways: mechanisms, structures, and advances in therapy
Wang, H., Guo, M., Wei, H., & Chen, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01347-1 · Cited by 1,016
The role of p53 in cancer drug resistance and targeted chemotherapy
Hientz, K., Mohr, A., Bhakta-Guha, D., & Efferth, T. (2017) · Oncotarget · doi:10.18632/oncotarget.13475 · Cited by 587
Mutant p53 as a target for cancer treatment
Duffy, M. J., Synnott, N. C., & Crown, J. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.06.023 · Cited by 364
Current and emerging therapeutic approaches for colorectal cancer: A comprehensive review
Kumar, A., Gautam, V., Sandhu, A., Rawat, K., Sharma, A., & Saha, L. (2023) · World Journal of Gastrointestinal Surgery · doi:10.4240/wjgs.v15.i4.495 · Cited by 272
Maslah, N., Salomao, N., Drevon, L., Verger, E., Partouche, N., Ly, P., Aubin, P., Naoui, N., Schlageter, M.-H., Bally, C., et al. (2020) · Haematologica · doi:10.3324/haematol.2019.218453 · Cited by 132
Metadata
- Authors
- Li, X.-L., Zhou, J., Chan, Z.-L., Chooi, J.-Y., Chen, Z.-R., & Chng, W.-J.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2015-10-01
- Volume
- 6
- Issue
- 34
- Pages
- 36689-36699
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W1893278446
- Cited by
- 48
- References
- 4
- FWCI
- 1.56
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.